

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B17

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/20	A1	(11) International Publication Number: WO 98/09621 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/GB97/02362 (22) International Filing Date: 2 September 1997 (02.09.97) (30) Priority Data: 9618420.5 4 September 1996 (04.09.96) GB (71) Applicant (for all designated States except US): SCOTIA HOLDINGS PLC [GB/GB]; Weyvern House, Weyvern Park, Portsmouth Road, Peasmarsh, Guildford, Surrey GU3 1NA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SCOTT, Catherine, Ann [GB/GB]; Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). HORROBIN, David, Frederick [GB/GB]; Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). (74) Agent: FARWELL, William, Robert; Phillips & Leigh, 7 Staple Inn, Holborn, London WC1V 7QF (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: FATTY ACID TREATMENT (57) Abstract The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

FATTY ACID TREATMENT

FIELD OF THE INVENTION

The invention relates to fatty acid treatment.

BACKGROUND

Chemotherapy, the use of drugs which aim either to kill cancer cells or to stop the spread of cancer, is now one of the most widely used types of treatment for cancer. It may be used either alone or in combination with one of the other modalities of cancer treatment, usually surgery or radiotherapy. Most chemotherapy regimes, other than those primarily targeted at the endocrine system such as anti-oestrogens and antiandrogens, cause important side effects. These side effects differ from drug to drug, but it is now common to use two, three, four or more drugs in combination in chemotherapy regimes and so most chemotherapy-treated patients will experience one or more of the typical consequences. The side effects include nausea, vomiting, suppression of the immune system, suppression of white blood cells and platelets, hair loss, cardiovascular damage, lung damage, renal damage, nerve damage and marked fatigue and malaise. Each drug has a specific range of side effects, some of which may be particularly important and limit the dose of the drug which can be given and so reduce the likelihood of a cure. Doxorubicin and related compounds, for example, can be severely cardiotoxic and this is a common dose-limiting side effect. Bleomycin, and to a lesser extent cyclophosphamide, can be toxic to the lungs causing fibrosis. The platinum derivatives and related compounds may be very toxic to the nerves.

We have been developing gamma-linolenic acid (GLA) and related compounds, including linoleic acid (LA), dihomogammalinolenic acid (DGLA), arachidonic acid (AA), stearidonic acid (SA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the treatment of cancer. These compounds which are all polyunsaturated lipids are cytotoxic to many cancer cells at concentrations which do not

harm normal cells and also have a range of anti-metastatic effects which may be operative at lower concentrations. We have come to the conclusion that many unsaturated fatty acids with carbon chain lengths from 14 to 26 and which contain two to six unsaturated double carbon-carbon bonds which may be either in the cis or the trans configuration can have anti-cancer actions. Other examples of such fatty acids include conjugated linoleic acid and parinaric acid, but the natural n-6 and n-3 EFAs are set out in the following:

n-6 EFAs		n-3 EFAs
18:2n-6 Linoleic acid (LA)		18:3n-3 α -linolenic acid (ALA)
↓	δ -6-desaturase	↓
18:3n-6 γ -Linolenic acid (GLA)		18:4n-3 Stearidonic acid, (SA)
↓	elongation	↓
20:3n-6 Dihomo- γ -linolenic acid (DGLA)		20:4n-3 Eicosatetraenoic acid
↓	δ -5-desaturase	↓
20:4n-6 Arachidonic acid (AA)		20:5n-3 Eicosapentaenoic acid (EPA)
↓	elongation	↓
22:4n-6 Adrenic acid (AdRA)		22:5n-3
↓	δ -4-desaturase	↓
22:5n-6		22:6n-3 Docosahexaenoic acid (DHA)

The acids, which in nature are of the all - cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. LA z,z-octadeca - 9,12 - dienoic acid or DHA z,z,z,z,z - docosa - 4,7,10,13,16,19 - hexanoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as correspondingly, 18:2 n-6 or 22:6 n-3, are convenient. Initials, e.g. EPA, and shortened forms of the name e.g. eicosapentaenoic acid, are used as trivial names in some instances.

CURRENT WORK

In a range of studies we have administered GLA, LA, EPA and DHA to patients with cancer and we are actively developing specific derivatives of these fatty acids as anti-cancer drugs. In many instances, the fatty acids have been given to patients who at that same time were receiving conventional chemotherapy for their cancer. We have repeatedly observed that many of the toxic side effects of chemotherapy are substantially reduced in patients who at the same time are receiving one or more of LA, GLA, EPA and DHA. On theoretical grounds, because of their similar chemical characteristics and modes of action we believe that many of the other fatty acids whose general characteristics are summarised in the previous paragraph will also have similar effects. The effects observed include reduced hair loss, reduced suppression of leukocytes and lymphocytes, reduced nausea and vomiting and in particular reduced fatigue and malaise. Our observations therefore indicate that GLA and EPA and related compounds may surprisingly have a broad spectrum of actions in reducing many different side effects of chemotherapy. We therefore propose their use in patients who are receiving chemotherapy for cancer to reduce the side effects of such chemotherapy, as set out in the claims herein.

We have recently supported the clinical observations by animal studies on the cardiotoxicity of doxorubicin and the lung toxicity of bleomycin. When 20 mg of

doxorubicin (DOX) is given intraperitoneally to mice, the animals usually die within two weeks because of cardiac damage. When animals were pre-treated with LA or with GLA or with EPA or with DHA in various doses and chemical forms, the death rate to the same dose of doxorubicin was reduced to between 20% and 60% depending on the dose and the precise chemical administered. In addition the reduction in cardiac weight, which is characteristic of doxorubicin toxicity, was considerably attenuated. Similarly, bleomycin introduced into the trachea of animals under anaesthesia at a dose of about 5-10 IU per kg body weight, within 2-4 weeks the animals develop severe lung fibrosis which is very similar to the fibrosis which occurs in human patients treated with bleomycin. Treatment with gamma-linolenic acid and linoleic acid could almost entirely suppress the lung pathological changes and the increased production of fibrous tissue. In a third animal study, the anti-cancer streptozotocin was used. A major effect of this compound is to damage the islet cells of the pancreas and consequently to lead to insulin dependent diabetes. Administration of LA, GLA or EPA prior to the streptozotocin greatly reduced the likelihood of the development of diabetes in rats. The ability of the fatty acids to suppress these very different forms of toxicity and the clinical observations which have been made in patients being treated with a wide range of drugs suggest that this is a method of preventing drug toxicity which has wide applicability.

THE INVENTION

The invention is as set out in the claims, but broadly lies in the use, in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy, particularly the side effects caused by any of the drugs listed herein, of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is administered.

Preferred fatty acids are LA, GLA, DGLA, SA, ALA, EPA and DHA, optionally administered or used with other fatty acids.

The drugs which have been used in anti-cancer chemotherapy in patients as referred to above include methotrexate, 5-fluorouracil, cyclophosphamide, cisplatin, doxorubicin, taxol and vincristine, but the invention provides a method of reducing the side effects resulting from any form of cancer chemotherapy resulting from drugs in any one of the classes mentioned below, or drugs similar to them which may be developed in the future:-

Folate antagonists such as methotrexate and trimetrexate

Pyrimidine antagonists such as 5-fluorouracil, fluorodeoxyuridine and azacytidine.

Purine antagonists such as mercaptopurine, thioguanine, tiazofurin, chlorodeoxyadenosine and pentostatin.

Sugar modified analogues such as cytarabine and fludarabine.

Ribonucleotide reductase inhibitors such as hydroxyurea.

Nitrogen mustards such as mechlorethamine, chlorambucil, melphalan cyclophosphamide and ifosfamide.

Aziridines such as thiotepa, altretamine and mitomycin.

Alkane sulfonates such as busulfan.

Nitrosoureas such as carmustine, lomustine, semustine and streptozotocin.

Platinum compounds such as cisplatin and carboplatin.

Methylating agents such as dacarbazine and procarbazine.

DNA-binding drugs such as daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, dactinomycin, bleomycin and plicamycin.

Topoisomerase inhibitors such as etoposide, teniposide, amascrine, camptothecin.

Microtubule active agents such as vinblastine, vincristine, vindosine, taxol and taxotere.

The fatty acids may be administered at the same time as the anti-cancer drugs or preferably both prior to and during therapy with the anti-cancer drugs themselves administered in amounts appropriate for the individual drug. The doses of the fatty acids may be from 1 mg to 100 g per day, preferably 50 mg to 50 g per day and very preferably 500 mg to 20 g per day. The fatty acids may be given in any appropriate form which leads to

an elevation of the fatty acid in the blood and cell membranes, including free fatty acids, simple esters of various sorts, salts including lithium salts, mono-, di- and tri-glycerides, mono- and di-esters of dihydric alcohols, ascorbyl and niacin derivatives, cholesterol esters, phospholipids and any other appropriate carriers. They may be given orally, parenterally or topically using any appropriate carrier or delivery systems or excipients known to those skilled in the art, including capsules, tablets, powders, liquids, emulsions and any other appropriate method.

FORMULATION EXAMPLES

The chemotherapy drugs can be administered in the manner conventional for each drug, itself known and no part of the invention. The fatty acids may be in any convenient form and the following are examples, suited also to the other fatty acids discussed.

1. Administration of 500 mg to 20 g of GLA per day in the form of soft or hard gelatine capsules or tablets providing:
 - a. 40 to 80 mg per capsule of GLA in the form of evening primrose oil.
 - b. 50-150 mg per capsule of GLA in the form of borage, blackcurrant, fungal or other appropriate oil.
 - c. 100-500 mg GLA per capsule in the form of triglyceride GLA, or any appropriate salt of GLA, such as the lithium or calcium or magnesium or zinc or potassium salts.
2. Administration of DGLA in a dose of 500 mg to 20 g per day in the forms of 1c above.
3. Administration of GLA or DGLA in association with EPA, with or without DHA, for example as a 40 to 80 mg GLA per capsule in the form of evening primrose oil together with 10 mg to 100 mg per capsule of EPA in the form of cold water marine fish oil.

4. Administration of GLA or DGLA in the form of a soluble powder or effervescent granule formed from any appropriate salt of GLA as in 1 c above and excipients such as citric acid monohydrate, sodium bicarbonate or other dibasic acids such as tartaric or maleic acid plus sweeteners such as sucrose or sorbitol and flavourings.
5. Administration of GLA or DGLA in the form of liquid evening primrose, borage or other appropriate oil as the oil itself or as a whip or emulsion prepared with appropriate flavours and stabilisers known to those skilled in the art.,
6. Administration of GLA or DGLA in any appropriate chemical form, microencapsulated using starch, gelatine, gum arabic or other appropriate formulation known to those skilled in the art.,
7. Administration of GLA in the form of pessaries, suppositories, skin patches or any other appropriate route.
8. A parenteral lipid emulsion is used containing 10% total lipid by volume in a per se conventional pyrogen-free formulation "INTRALIPID" oil in water emulsion (trade mark, Kabi-Vitrum) containing per 500 ml water at pH7:-

Fractionated Soybean oil	50g
Fractionated egg phospholipids	6g
Glycerol	11g

According to the invention (a) 5%, (b) 10% or (c) 15% of the lipid present, by weight, is taken up by one or other of the mixtures of EFAs below, the EFAs being provided as triglycerides, or free fatty acids, or ethyl esters, or diol esters as in our PCT specifications WO 96/34846 (PCT GB 96/01053) and WO 96/34855 (PCT GB 96 01052), or appropriate salts, including the lithium salts. The following figures show the proportional composition of the added EFA or EFA mixture:-

GLA	DGLA	SA	EPA	DHA
100	-	-	-	-
50	50	-	-	-
50	-	50	-	-
50	-	-	30	20
-	60	-	20	20
-	80	20	-	-
80	-	-	20	10
-	-	-	80	20

9. An oil-in-water oral emulsion (batch size 200g) was prepared containing the following ingredients, the galactolipid being as described in PCT specification WO 95/20943 (PCT SE 95/00115):-

<u>Ingredients</u>	<u>% wt.</u>
Emulsifier (galactolipid)*	2.00
1,3-Propane diol diester (GLA-EPA)	20.00
(as in Example 8)	
Ascorbyl palmitate (AP)	0.02
Vitamin E	0.5
Water	to 100.00

The emulsifier-galactolipid was dispersed in the diester, and the Vitamin E, AP and water were mixed. The oil phase was added to the aqueous phase under a high shear mix (Ultraturrax - trade mark) at speed 4, for a few minutes. This pre-emulsion was then homogenised at 80 MPA and at 50°C for 6 cycles (mini-Lab 8.30 H; APV Rannie AS, Denmark). The emulsion formed had an average droplet size of 230nm.

CASE HISTORIES

The following histories illustrate use of the invention

- A. A patient with malignant brain cancer, a glioblastoma, was treated in addition to surgery with the nitrosourea, carmustine. Prior to and during the carmustine course the patient was also receiving gamma-linolenic acid and linoleic acid in the form of the triglyceride dilinoleoyl-monogammalinolenoyl-glycerol (DLMG). Carmustine normally causes marked nausea and vomiting, anorexia and severe malaise. In contrast, this patient experienced only very mild nausea and felt well throughout indicating reduction of the side effects by the DLMG.
- B. A patient with Hodgkin's disease was treated with the 'MOPP' regime (carmustine, vincristine, procarbazine and prednisone). For one week prior to the start of the chemotherapy regime, and throughout the course of chemotherapy, this 40 year old man also received 3g per day orally of the lithium salt of gammalinolenic acid. This chemotherapy regime normally causes severe vomiting and nausea, marked malaise and anorexia. In contrast, this patient experienced only mild nausea and remained well and able to continue working.
- C. A 50 year old woman with breast cancer was treated with the 'CMF' regime (cyclophosphamide, methotrexate and 5-fluorouracil). This regime was started one week after receiving a cumulative dose of 30 g of gammalinolenic acid intravenously as the lithium salt with continued treatment with 2 g/day of oral lithium gammalinolenate. The chemotherapy regime normally causes nausea, vomiting, mucositis and white cell suppression. In contrast, this woman experienced only mild nausea with no vomiting or mucositis and the suppression of the white cell count was less than expected.

D. A 55 year old man with metastatic colon cancer was treated with 5-fluorouracil. This normally causes nausea, vomiting, white cell suppression and mucositis. For two weeks prior to the chemotherapy and during the whole of the chemotherapy course, the man also received 3g/day of the pure triglyceride of eicosapentaenoic acid. There was no vomiting or mucositis and the nausea and white cell suppression were less than expected.

CLAIMS

1. The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy, particularly the side effects caused by any of the drugs listed herein, of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.
2. Use or method according to claim 1 wherein the fatty acid is selected from LA, GLA, DGLA, SA, ALA, EPA and DHA, optionally administered or used with other fatty acids.
3. Use or method according to claim 1 wherein the drug is doxorubicin or a related compound which causes cardiotoxicity.
4. Use or method according to claim 1 wherein the drug is bleomycin or a related compound which causes lung toxicity.
5. Use or method according to claim 1 wherein the drug is cisplatin or a related compound which causes neurotoxicity.
6. Use or method according to claim 1 wherein the drug is doxorubicin or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.
7. Use or method according to claim 1 wherein the drug is bleomycin, cyclophosphamide or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.

8. Use or method according to claim 1 wherein the drug is cisplatin or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02362

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 8849 Derwent Publications Ltd., London, GB; AN 88-348779 XP002054538 & JP 63 258 816 A (NIPPON OILS & FATS CO. LTD.) , 16 April 1987 see abstract	1-8
X	FERGUSON PJ: "Cytotoxic and chemomodulative effects of gamma-linolenic acid (GLA) against a human squamous carcinoma line and multidrug-resistant (MDR) and carboplatin-resistant (CP-R) variants (Meeting abstract)." PROC ANNU MEET AM ASSOC CANCER RES;36:A1722 1995, XP002054537 see abstract	1,2,5,8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 February 1998

Date of mailing of the international search report

20/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Mair, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 257 939 A (EFAMOL LIMITED) 2 March 1988 see the whole document ---	1,2,5,8
X	GB 2 114 885 A (YAMANOUCHI PHARMACEUTICAL CO. LTD.) 1 September 1983 see page 1, lefthand column, line 10-36 & 56-58 -----	1-8

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/GB 97/02362

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 257939 A	02-03-88	AU 600298 B	09-08-90
		AU 7726087 A	03-03-88
		CA 1319681 A	29-06-93
		IE 60416 B	13-07-94
		JP 63068595 A	28-03-88
		KR 9604308 B	30-03-96
		US 4937262 A	26-06-90
		ZA 8706074 A	25-02-88
<hr/>			
GB 2114885 A	01-09-83	JP 1732970 C	17-02-93
		JP 4020887 B	07-04-92
		JP 58124714 A	25-07-83
		DE 3301638 A	04-08-83
		FR 2519864 A	22-07-83
		US 4578391 A	25-03-86
<hr/>			